<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="230057">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084864</url>
  </required_header>
  <id_info>
    <org_study_id>RP 02-12</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <secondary_id>RPCI-RP-0212</secondary_id>
    <nct_id>NCT00084864</nct_id>
  </id_info>
  <brief_title>Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate</brief_title>
  <official_title>A Pilot Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Potential Intermediate Endpoints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Calcitriol and dexamethasone may slow the growth of prostate cancer cells.

      PURPOSE: This randomized phase II trial is studying how well giving calcitriol together with
      dexamethasone before radical prostatectomy works in treating patients with localized stage
      II or stage III adenocarcinoma (cancer) of the prostate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the effect of calcitriol and dexamethasone before radical prostatectomy on
           tumor vessel density in patients with localized adenocarcinoma of the prostate.

        -  Determine the effect of this regimen on the extent of prostatic intraepithelial
           neoplasia in these patients.

        -  Determine the effect of this regimen on the expression of apoptosis markers, p21, p27,
           prostate-specific antigen (PSA), prostate-specific membrane antigen, and VDR expression
           in tumor-associated vascular endothelial cells and endothelium derived from
           normal-appearing prostate and tumor in these patients.

        -  Determine the acute effects of this regimen on serum PSA in these patients.

        -  Determine the toxicity of this regimen in these patients.

      OUTLINE: This is a two-stage, randomized, pilot study.

        -  Stage 1: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive oral dexamethasone once daily on days 1-4 and oral
                calcitriol once daily on days 2-4 weekly for 4 weeks before surgery. Within 48
                hours of the last dose, patients undergo radical prostatectomy.

             -  Arm II: Patients receive no study drugs, but undergo radical prostatectomy.

        -  Stage 2: If sufficient activity is seen with the dexamethasone and calcitriol regimen
           in stage 1, the study is expanded and additional patients are randomized to 1 of 4
           treatment arms.

             -  Arm I: Patients receive dexamethasone and calcitriol as in stage 1, arm I.

             -  Arm II: Patients receive oral dexamethasone once daily on days 1-4.

             -  Arm III: Patients receive oral calcitriol once daily on days 2-4.

             -  Arm IV: Patients undergo radical prostatectomy as in stage 1, arm II. In arms I,
                II, and III, patients undergo radical prostatectomy as in stage 1, arm I.

      Patients are followed at 1, 3, and 12 months.

      PROJECTED ACCRUAL: A total of 20-80 patients (20 for stage 1 [10 per treatment arm] and 60
      for stage 2) will be accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sample size is too small to draw a conclusion
  </why_stopped>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of preoperative high-dose calcitriol and dexamethasone on prostatic tumor vessel density measured at 1, 2, 3, and 12 months post prostatectomy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of preoperative high-dose calcitriol and dexamethasone on extent of prostatic intraepithelial neoplasia (PIN) at 1, 2, 3, and 12 months post prostatectomy</measure>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Stage 1, Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1, Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No study drugs before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2, Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dexamethasone and calcitriol as in stage 1, arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2, Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral dexamethasone once daily on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2, Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral calcitriol once daily on days 2-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2, Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients do not receive study drugs before surgery as in stage 1, arm II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcitriol</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Stage 1, Arm I</arm_group_label>
    <arm_group_label>Stage 2, Arm I</arm_group_label>
    <arm_group_label>Stage 2, Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Stage 1, Arm I</arm_group_label>
    <arm_group_label>Stage 2, Arm I</arm_group_label>
    <arm_group_label>Stage 2, Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical observation</intervention_name>
    <description>No intervention before surgery</description>
    <arm_group_label>Stage 1, Arm II</arm_group_label>
    <arm_group_label>Stage 2, Arm IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Organ-confined disease

               -  cT1, cT2, or cT3 tumors

                    -  Patients with cT1 tumors are eligible if ≥ 1 core biopsies have ≥ 50% of
                       the tumor OR if 50% of the cores examined contain the tumor

               -  No small cell carcinoma of the prostate

          -  Scheduled for radical prostatectomy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Platelet count ≥ 100,000/mm^3

          -  WBC ≥ 3,500/mm^3

        Hepatic

          -  ALT and AST ≤ 4 times normal

          -  Bilirubin ≤ 2 mg/dL

        Renal

          -  Creatinine ≤ 2 times upper limit of normal

          -  Calcium ≤ 10.5 mg/dL

          -  No detectable renal stones by CT scan or ultrasound

        Other

          -  No history of diabetes mellitus requiring pharmacotherapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  More than 5 years since prior antiestrogens, antiandrogens, luteinizing
             hormone-releasing hormone agonists, estrogen, or progestational agents

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

          -  No prior nephrectomy

          -  No prior prostatic surgery

          -  No prior cryotherapy or transurethral resection of the prostate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald L. Trump, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 9, 2016</lastchanged_date>
  <firstreceived_date>June 10, 2004</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
